nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—CYP3A4—prostate cancer	0.238	1	CbGaD
Linagliptin—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0597	0.112	CbGbCtD
Linagliptin—ABCB1—Estramustine—prostate cancer	0.0487	0.0915	CbGbCtD
Linagliptin—ABCB1—Cabazitaxel—prostate cancer	0.0321	0.0603	CbGbCtD
Linagliptin—CYP3A4—Bicalutamide—prostate cancer	0.0314	0.059	CbGbCtD
Linagliptin—ABCB1—Estrone—prostate cancer	0.0314	0.059	CbGbCtD
Linagliptin—CYP3A4—Estramustine—prostate cancer	0.0292	0.0548	CbGbCtD
Linagliptin—ABCB1—Ethinyl Estradiol—prostate cancer	0.028	0.0526	CbGbCtD
Linagliptin—CYP3A4—Flutamide—prostate cancer	0.026	0.0489	CbGbCtD
Linagliptin—CYP3A4—Abiraterone—prostate cancer	0.026	0.0489	CbGbCtD
Linagliptin—ABCB1—Conjugated Estrogens—prostate cancer	0.0205	0.0386	CbGbCtD
Linagliptin—CYP3A4—Cabazitaxel—prostate cancer	0.0192	0.0361	CbGbCtD
Linagliptin—CYP3A4—Estrone—prostate cancer	0.0188	0.0353	CbGbCtD
Linagliptin—ABCB1—Mitoxantrone—prostate cancer	0.0187	0.0351	CbGbCtD
Linagliptin—ABCB1—Estradiol—prostate cancer	0.018	0.0339	CbGbCtD
Linagliptin—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0168	0.0315	CbGbCtD
Linagliptin—ABCB1—Prednisone—prostate cancer	0.0155	0.0291	CbGbCtD
Linagliptin—CYP3A4—Conjugated Estrogens—prostate cancer	0.0123	0.0231	CbGbCtD
Linagliptin—ABCB1—Etoposide—prostate cancer	0.0118	0.0221	CbGbCtD
Linagliptin—CYP3A4—Mitoxantrone—prostate cancer	0.0112	0.021	CbGbCtD
Linagliptin—CYP3A4—Estradiol—prostate cancer	0.0108	0.0203	CbGbCtD
Linagliptin—ABCB1—Docetaxel—prostate cancer	0.0108	0.0202	CbGbCtD
Linagliptin—CYP3A4—Prednisone—prostate cancer	0.00928	0.0174	CbGbCtD
Linagliptin—ABCB1—Doxorubicin—prostate cancer	0.00803	0.0151	CbGbCtD
Linagliptin—CYP3A4—Etoposide—prostate cancer	0.00705	0.0132	CbGbCtD
Linagliptin—CYP3A4—Docetaxel—prostate cancer	0.00645	0.0121	CbGbCtD
Linagliptin—CYP3A4—Doxorubicin—prostate cancer	0.00481	0.00904	CbGbCtD
Linagliptin—DPP4—prostate gland—prostate cancer	0.00251	0.146	CbGeAlD
Linagliptin—CYP3A4—urine—prostate cancer	0.00228	0.132	CbGeAlD
Linagliptin—DPP4—seminal vesicle—prostate cancer	0.00212	0.123	CbGeAlD
Linagliptin—DPP4—epithelium—prostate cancer	0.00185	0.107	CbGeAlD
Linagliptin—Alogliptin—CYP3A4—prostate cancer	0.00172	1	CrCbGaD
Linagliptin—DPP4—renal system—prostate cancer	0.00171	0.0992	CbGeAlD
Linagliptin—DPP4—bone marrow—prostate cancer	0.00129	0.075	CbGeAlD
Linagliptin—DPP4—testis—prostate cancer	0.00111	0.0641	CbGeAlD
Linagliptin—DPP4—lymph node—prostate cancer	0.000802	0.0465	CbGeAlD
Linagliptin—ABCB1—prostate gland—prostate cancer	0.00058	0.0336	CbGeAlD
Linagliptin—CYP3A4—renal system—prostate cancer	0.000558	0.0324	CbGeAlD
Linagliptin—ABCB1—seminal vesicle—prostate cancer	0.00049	0.0284	CbGeAlD
Linagliptin—ABCB1—epithelium—prostate cancer	0.000426	0.0247	CbGeAlD
Linagliptin—ABCB1—renal system—prostate cancer	0.000395	0.0229	CbGeAlD
Linagliptin—ABCB1—urethra—prostate cancer	0.000388	0.0225	CbGeAlD
Linagliptin—Urinary tract infection—Estradiol—prostate cancer	0.000365	0.00242	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Mitoxantrone—prostate cancer	0.000364	0.00242	CcSEcCtD
Linagliptin—Infection—Ethinyl Estradiol—prostate cancer	0.000364	0.00242	CcSEcCtD
Linagliptin—Back pain—Goserelin—prostate cancer	0.000358	0.00238	CcSEcCtD
Linagliptin—Weight increased—Mitoxantrone—prostate cancer	0.000357	0.00237	CcSEcCtD
Linagliptin—Skin disorder—Ethinyl Estradiol—prostate cancer	0.000356	0.00237	CcSEcCtD
Linagliptin—Rash—Estradiol valerate/Dienogest—prostate cancer	0.000356	0.00236	CcSEcCtD
Linagliptin—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.000356	0.00236	CcSEcCtD
Linagliptin—Skin exfoliation—Prednisone—prostate cancer	0.000356	0.00236	CcSEcCtD
Linagliptin—Back pain—Conjugated Estrogens—prostate cancer	0.000354	0.00235	CcSEcCtD
Linagliptin—Headache—Estradiol valerate/Dienogest—prostate cancer	0.000354	0.00235	CcSEcCtD
Linagliptin—Diabetes mellitus—Capecitabine—prostate cancer	0.000349	0.00232	CcSEcCtD
Linagliptin—Diarrhoea—Cabazitaxel—prostate cancer	0.000346	0.0023	CcSEcCtD
Linagliptin—Urticaria—Bicalutamide—prostate cancer	0.000345	0.00229	CcSEcCtD
Linagliptin—Urinary tract infection—Mitoxantrone—prostate cancer	0.00034	0.00226	CcSEcCtD
Linagliptin—Rash—Degarelix—prostate cancer	0.000339	0.00225	CcSEcCtD
Linagliptin—Dermatitis—Degarelix—prostate cancer	0.000338	0.00225	CcSEcCtD
Linagliptin—Headache—Degarelix—prostate cancer	0.000336	0.00223	CcSEcCtD
Linagliptin—Angioedema—Conjugated Estrogens—prostate cancer	0.000335	0.00222	CcSEcCtD
Linagliptin—Cough—Goserelin—prostate cancer	0.000323	0.00214	CcSEcCtD
Linagliptin—Hypersensitivity—Bicalutamide—prostate cancer	0.00032	0.00212	CcSEcCtD
Linagliptin—Cough—Conjugated Estrogens—prostate cancer	0.00032	0.00212	CcSEcCtD
Linagliptin—Headache—Cabazitaxel—prostate cancer	0.000317	0.0021	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.000317	0.0021	CcSEcCtD
Linagliptin—Myalgia—Goserelin—prostate cancer	0.000315	0.00209	CcSEcCtD
Linagliptin—Arthralgia—Goserelin—prostate cancer	0.000315	0.00209	CcSEcCtD
Linagliptin—Constipation—Ethinyl Estradiol—prostate cancer	0.000314	0.00208	CcSEcCtD
Linagliptin—Pain in extremity—Docetaxel—prostate cancer	0.000314	0.00208	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Goserelin—prostate cancer	0.000313	0.00208	CcSEcCtD
Linagliptin—Myalgia—Conjugated Estrogens—prostate cancer	0.000312	0.00207	CcSEcCtD
Linagliptin—Arthralgia—Conjugated Estrogens—prostate cancer	0.000312	0.00207	CcSEcCtD
Linagliptin—Diabetes mellitus—Prednisone—prostate cancer	0.000311	0.00206	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—prostate cancer	0.00031	0.00206	CcSEcCtD
Linagliptin—Immune system disorder—Estradiol—prostate cancer	0.000304	0.00202	CcSEcCtD
Linagliptin—Pain in extremity—Capecitabine—prostate cancer	0.000304	0.00202	CcSEcCtD
Linagliptin—Mediastinal disorder—Estradiol—prostate cancer	0.000304	0.00202	CcSEcCtD
Linagliptin—Anaphylactic shock—Goserelin—prostate cancer	0.000302	0.002	CcSEcCtD
Linagliptin—Infection—Goserelin—prostate cancer	0.0003	0.00199	CcSEcCtD
Linagliptin—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.000299	0.00199	CcSEcCtD
Linagliptin—ABCB1—bone marrow—prostate cancer	0.000299	0.0173	CbGeAlD
Linagliptin—Infection—Conjugated Estrogens—prostate cancer	0.000297	0.00197	CcSEcCtD
Linagliptin—Diarrhoea—Bicalutamide—prostate cancer	0.000297	0.00197	CcSEcCtD
Linagliptin—Malnutrition—Estradiol—prostate cancer	0.000293	0.00195	CcSEcCtD
Linagliptin—Skin disorder—Goserelin—prostate cancer	0.000293	0.00195	CcSEcCtD
Linagliptin—Urticaria—Ethinyl Estradiol—prostate cancer	0.000291	0.00193	CcSEcCtD
Linagliptin—Infestation NOS—Etoposide—prostate cancer	0.000291	0.00193	CcSEcCtD
Linagliptin—Infestation—Etoposide—prostate cancer	0.000291	0.00193	CcSEcCtD
Linagliptin—Skin disorder—Conjugated Estrogens—prostate cancer	0.00029	0.00193	CcSEcCtD
Linagliptin—Back pain—Estradiol—prostate cancer	0.000284	0.00188	CcSEcCtD
Linagliptin—Nasopharyngitis—Docetaxel—prostate cancer	0.00028	0.00186	CcSEcCtD
Linagliptin—Skin exfoliation—Epirubicin—prostate cancer	0.000278	0.00185	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Goserelin—prostate cancer	0.000275	0.00183	CcSEcCtD
Linagliptin—Rash—Bicalutamide—prostate cancer	0.000274	0.00182	CcSEcCtD
Linagliptin—Dermatitis—Bicalutamide—prostate cancer	0.000273	0.00182	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Conjugated Estrogens—prostate cancer	0.000272	0.00181	CcSEcCtD
Linagliptin—Headache—Bicalutamide—prostate cancer	0.000272	0.00181	CcSEcCtD
Linagliptin—Nasopharyngitis—Capecitabine—prostate cancer	0.000272	0.0018	CcSEcCtD
Linagliptin—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.00027	0.00179	CcSEcCtD
Linagliptin—Angioedema—Estradiol—prostate cancer	0.000268	0.00178	CcSEcCtD
Linagliptin—Back pain—Mitoxantrone—prostate cancer	0.000264	0.00175	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000258	0.00171	CcSEcCtD
Linagliptin—Constipation—Goserelin—prostate cancer	0.000258	0.00171	CcSEcCtD
Linagliptin—Skin exfoliation—Doxorubicin—prostate cancer	0.000257	0.00171	CcSEcCtD
Linagliptin—Cough—Estradiol—prostate cancer	0.000256	0.0017	CcSEcCtD
Linagliptin—Constipation—Conjugated Estrogens—prostate cancer	0.000256	0.0017	CcSEcCtD
Linagliptin—ABCB1—testis—prostate cancer	0.000255	0.0148	CbGeAlD
Linagliptin—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000251	0.00167	CcSEcCtD
Linagliptin—Arthralgia—Estradiol—prostate cancer	0.00025	0.00166	CcSEcCtD
Linagliptin—Myalgia—Estradiol—prostate cancer	0.00025	0.00166	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.000248	0.00165	CcSEcCtD
Linagliptin—Weight increased—Docetaxel—prostate cancer	0.000247	0.00164	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Capecitabine—prostate cancer	0.000244	0.00162	CcSEcCtD
Linagliptin—Diabetes mellitus—Epirubicin—prostate cancer	0.000243	0.00161	CcSEcCtD
Linagliptin—Infestation NOS—Docetaxel—prostate cancer	0.000242	0.0016	CcSEcCtD
Linagliptin—Infestation—Docetaxel—prostate cancer	0.000242	0.0016	CcSEcCtD
Linagliptin—Urticaria—Goserelin—prostate cancer	0.00024	0.00159	CcSEcCtD
Linagliptin—Anaphylactic shock—Estradiol—prostate cancer	0.000239	0.00159	CcSEcCtD
Linagliptin—Weight increased—Capecitabine—prostate cancer	0.000239	0.00159	CcSEcCtD
Linagliptin—Cough—Mitoxantrone—prostate cancer	0.000238	0.00158	CcSEcCtD
Linagliptin—Infection—Estradiol—prostate cancer	0.000238	0.00158	CcSEcCtD
Linagliptin—Urticaria—Conjugated Estrogens—prostate cancer	0.000238	0.00158	CcSEcCtD
Linagliptin—Immune system disorder—Etoposide—prostate cancer	0.000236	0.00157	CcSEcCtD
Linagliptin—Mediastinal disorder—Etoposide—prostate cancer	0.000235	0.00156	CcSEcCtD
Linagliptin—Infestation NOS—Capecitabine—prostate cancer	0.000234	0.00155	CcSEcCtD
Linagliptin—Infestation—Capecitabine—prostate cancer	0.000234	0.00155	CcSEcCtD
Linagliptin—Arthralgia—Mitoxantrone—prostate cancer	0.000233	0.00154	CcSEcCtD
Linagliptin—Myalgia—Mitoxantrone—prostate cancer	0.000233	0.00154	CcSEcCtD
Linagliptin—Skin disorder—Estradiol—prostate cancer	0.000232	0.00154	CcSEcCtD
Linagliptin—Rash—Ethinyl Estradiol—prostate cancer	0.000231	0.00154	CcSEcCtD
Linagliptin—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000231	0.00153	CcSEcCtD
Linagliptin—Headache—Ethinyl Estradiol—prostate cancer	0.00023	0.00153	CcSEcCtD
Linagliptin—Pancreatitis—Prednisone—prostate cancer	0.000229	0.00152	CcSEcCtD
Linagliptin—Urinary tract infection—Capecitabine—prostate cancer	0.000227	0.00151	CcSEcCtD
Linagliptin—Diabetes mellitus—Doxorubicin—prostate cancer	0.000225	0.00149	CcSEcCtD
Linagliptin—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000223	0.00148	CcSEcCtD
Linagliptin—Hypersensitivity—Goserelin—prostate cancer	0.000222	0.00148	CcSEcCtD
Linagliptin—Infection—Mitoxantrone—prostate cancer	0.000222	0.00147	CcSEcCtD
Linagliptin—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.00022	0.00146	CcSEcCtD
Linagliptin—Back pain—Etoposide—prostate cancer	0.00022	0.00146	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Estradiol—prostate cancer	0.000218	0.00145	CcSEcCtD
Linagliptin—Hypoglycaemia—Epirubicin—prostate cancer	0.000217	0.00144	CcSEcCtD
Linagliptin—Skin disorder—Mitoxantrone—prostate cancer	0.000217	0.00144	CcSEcCtD
Linagliptin—Weight increased—Prednisone—prostate cancer	0.000213	0.00141	CcSEcCtD
Linagliptin—Pain in extremity—Epirubicin—prostate cancer	0.000212	0.0014	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Estradiol—prostate cancer	0.000207	0.00137	CcSEcCtD
Linagliptin—Diarrhoea—Goserelin—prostate cancer	0.000207	0.00137	CcSEcCtD
Linagliptin—Constipation—Estradiol—prostate cancer	0.000205	0.00136	CcSEcCtD
Linagliptin—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000205	0.00136	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.000203	0.00135	CcSEcCtD
Linagliptin—Hypoglycaemia—Doxorubicin—prostate cancer	0.000201	0.00133	CcSEcCtD
Linagliptin—Cough—Etoposide—prostate cancer	0.000198	0.00132	CcSEcCtD
Linagliptin—Immune system disorder—Docetaxel—prostate cancer	0.000196	0.0013	CcSEcCtD
Linagliptin—Pain in extremity—Doxorubicin—prostate cancer	0.000196	0.0013	CcSEcCtD
Linagliptin—Mediastinal disorder—Docetaxel—prostate cancer	0.000196	0.0013	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000192	0.00128	CcSEcCtD
Linagliptin—Constipation—Mitoxantrone—prostate cancer	0.000191	0.00127	CcSEcCtD
Linagliptin—Rash—Goserelin—prostate cancer	0.00019	0.00126	CcSEcCtD
Linagliptin—Dermatitis—Goserelin—prostate cancer	0.00019	0.00126	CcSEcCtD
Linagliptin—Urticaria—Estradiol—prostate cancer	0.00019	0.00126	CcSEcCtD
Linagliptin—Immune system disorder—Capecitabine—prostate cancer	0.00019	0.00126	CcSEcCtD
Linagliptin—Mediastinal disorder—Capecitabine—prostate cancer	0.000189	0.00126	CcSEcCtD
Linagliptin—Nasopharyngitis—Epirubicin—prostate cancer	0.000189	0.00126	CcSEcCtD
Linagliptin—Headache—Goserelin—prostate cancer	0.000189	0.00126	CcSEcCtD
Linagliptin—Malnutrition—Docetaxel—prostate cancer	0.000189	0.00125	CcSEcCtD
Linagliptin—Rash—Conjugated Estrogens—prostate cancer	0.000189	0.00125	CcSEcCtD
Linagliptin—Dermatitis—Conjugated Estrogens—prostate cancer	0.000188	0.00125	CcSEcCtD
Linagliptin—Headache—Conjugated Estrogens—prostate cancer	0.000187	0.00124	CcSEcCtD
Linagliptin—Anaphylactic shock—Etoposide—prostate cancer	0.000185	0.00123	CcSEcCtD
Linagliptin—ABCB1—lymph node—prostate cancer	0.000185	0.0107	CbGeAlD
Linagliptin—Infection—Etoposide—prostate cancer	0.000184	0.00122	CcSEcCtD
Linagliptin—Malnutrition—Capecitabine—prostate cancer	0.000183	0.00121	CcSEcCtD
Linagliptin—Back pain—Docetaxel—prostate cancer	0.000183	0.00121	CcSEcCtD
Linagliptin—Skin disorder—Etoposide—prostate cancer	0.00018	0.0012	CcSEcCtD
Linagliptin—Pancreatitis—Epirubicin—prostate cancer	0.000179	0.00119	CcSEcCtD
Linagliptin—Urticaria—Mitoxantrone—prostate cancer	0.000177	0.00118	CcSEcCtD
Linagliptin—Back pain—Capecitabine—prostate cancer	0.000177	0.00117	CcSEcCtD
Linagliptin—Hypersensitivity—Estradiol—prostate cancer	0.000176	0.00117	CcSEcCtD
Linagliptin—Nasopharyngitis—Doxorubicin—prostate cancer	0.000175	0.00116	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Epirubicin—prostate cancer	0.00017	0.00113	CcSEcCtD
Linagliptin—Immune system disorder—Prednisone—prostate cancer	0.000169	0.00112	CcSEcCtD
Linagliptin—Weight increased—Epirubicin—prostate cancer	0.000166	0.0011	CcSEcCtD
Linagliptin—Pancreatitis—Doxorubicin—prostate cancer	0.000166	0.0011	CcSEcCtD
Linagliptin—Cough—Docetaxel—prostate cancer	0.000165	0.00109	CcSEcCtD
Linagliptin—Hypersensitivity—Mitoxantrone—prostate cancer	0.000164	0.00109	CcSEcCtD
Linagliptin—Diarrhoea—Estradiol—prostate cancer	0.000164	0.00109	CcSEcCtD
Linagliptin—Infestation—Epirubicin—prostate cancer	0.000163	0.00108	CcSEcCtD
Linagliptin—Infestation NOS—Epirubicin—prostate cancer	0.000163	0.00108	CcSEcCtD
Linagliptin—Malnutrition—Prednisone—prostate cancer	0.000163	0.00108	CcSEcCtD
Linagliptin—Arthralgia—Docetaxel—prostate cancer	0.000161	0.00107	CcSEcCtD
Linagliptin—Myalgia—Docetaxel—prostate cancer	0.000161	0.00107	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Etoposide—prostate cancer	0.00016	0.00106	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.00016	0.00106	CcSEcCtD
Linagliptin—Cough—Capecitabine—prostate cancer	0.00016	0.00106	CcSEcCtD
Linagliptin—Constipation—Etoposide—prostate cancer	0.000159	0.00105	CcSEcCtD
Linagliptin—Urinary tract infection—Epirubicin—prostate cancer	0.000158	0.00105	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Doxorubicin—prostate cancer	0.000157	0.00104	CcSEcCtD
Linagliptin—Arthralgia—Capecitabine—prostate cancer	0.000156	0.00103	CcSEcCtD
Linagliptin—Myalgia—Capecitabine—prostate cancer	0.000156	0.00103	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000155	0.00103	CcSEcCtD
Linagliptin—Anaphylactic shock—Docetaxel—prostate cancer	0.000154	0.00102	CcSEcCtD
Linagliptin—Weight increased—Doxorubicin—prostate cancer	0.000154	0.00102	CcSEcCtD
Linagliptin—Infection—Docetaxel—prostate cancer	0.000153	0.00102	CcSEcCtD
Linagliptin—Diarrhoea—Mitoxantrone—prostate cancer	0.000153	0.00101	CcSEcCtD
Linagliptin—Rash—Estradiol—prostate cancer	0.000151	0.001	CcSEcCtD
Linagliptin—Infestation NOS—Doxorubicin—prostate cancer	0.000151	0.001	CcSEcCtD
Linagliptin—Infestation—Doxorubicin—prostate cancer	0.000151	0.001	CcSEcCtD
Linagliptin—Dermatitis—Estradiol—prostate cancer	0.000151	0.001	CcSEcCtD
Linagliptin—Headache—Estradiol—prostate cancer	0.00015	0.000995	CcSEcCtD
Linagliptin—Skin disorder—Docetaxel—prostate cancer	0.00015	0.000994	CcSEcCtD
Linagliptin—Angioedema—Prednisone—prostate cancer	0.000149	0.000988	CcSEcCtD
Linagliptin—Infection—Capecitabine—prostate cancer	0.000148	0.000984	CcSEcCtD
Linagliptin—Urticaria—Etoposide—prostate cancer	0.000147	0.000978	CcSEcCtD
Linagliptin—Urinary tract infection—Doxorubicin—prostate cancer	0.000147	0.000974	CcSEcCtD
Linagliptin—Skin disorder—Capecitabine—prostate cancer	0.000145	0.000963	CcSEcCtD
Linagliptin—Rash—Mitoxantrone—prostate cancer	0.000141	0.000934	CcSEcCtD
Linagliptin—Dermatitis—Mitoxantrone—prostate cancer	0.00014	0.000933	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.00014	0.000932	CcSEcCtD
Linagliptin—Headache—Mitoxantrone—prostate cancer	0.00014	0.000928	CcSEcCtD
Linagliptin—Arthralgia—Prednisone—prostate cancer	0.000139	0.000921	CcSEcCtD
Linagliptin—Myalgia—Prednisone—prostate cancer	0.000139	0.000921	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000138	0.000914	CcSEcCtD
Linagliptin—Hypersensitivity—Etoposide—prostate cancer	0.000137	0.000907	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000136	0.000903	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000133	0.000884	CcSEcCtD
Linagliptin—Anaphylactic shock—Prednisone—prostate cancer	0.000133	0.000883	CcSEcCtD
Linagliptin—Immune system disorder—Epirubicin—prostate cancer	0.000132	0.000878	CcSEcCtD
Linagliptin—Infection—Prednisone—prostate cancer	0.000132	0.000877	CcSEcCtD
Linagliptin—Mediastinal disorder—Epirubicin—prostate cancer	0.000132	0.000876	CcSEcCtD
Linagliptin—Constipation—Docetaxel—prostate cancer	0.000132	0.000875	CcSEcCtD
Linagliptin—Skin disorder—Prednisone—prostate cancer	0.000129	0.000857	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000129	0.000856	CcSEcCtD
Linagliptin—Constipation—Capecitabine—prostate cancer	0.000128	0.000847	CcSEcCtD
Linagliptin—Malnutrition—Epirubicin—prostate cancer	0.000127	0.000846	CcSEcCtD
Linagliptin—Diarrhoea—Etoposide—prostate cancer	0.000127	0.000843	CcSEcCtD
Linagliptin—Back pain—Epirubicin—prostate cancer	0.000123	0.000818	CcSEcCtD
Linagliptin—Immune system disorder—Doxorubicin—prostate cancer	0.000122	0.000812	CcSEcCtD
Linagliptin—Mediastinal disorder—Doxorubicin—prostate cancer	0.000122	0.00081	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000121	0.000804	CcSEcCtD
Linagliptin—Urticaria—Capecitabine—prostate cancer	0.000119	0.000787	CcSEcCtD
Linagliptin—Malnutrition—Doxorubicin—prostate cancer	0.000118	0.000783	CcSEcCtD
Linagliptin—Rash—Etoposide—prostate cancer	0.000117	0.000777	CcSEcCtD
Linagliptin—Dermatitis—Etoposide—prostate cancer	0.000117	0.000776	CcSEcCtD
Linagliptin—Headache—Etoposide—prostate cancer	0.000116	0.000772	CcSEcCtD
Linagliptin—Back pain—Doxorubicin—prostate cancer	0.000114	0.000757	CcSEcCtD
Linagliptin—Constipation—Prednisone—prostate cancer	0.000114	0.000755	CcSEcCtD
Linagliptin—Hypersensitivity—Docetaxel—prostate cancer	0.000114	0.000754	CcSEcCtD
Linagliptin—Cough—Epirubicin—prostate cancer	0.000111	0.000738	CcSEcCtD
Linagliptin—Hypersensitivity—Capecitabine—prostate cancer	0.00011	0.00073	CcSEcCtD
Linagliptin—Arthralgia—Epirubicin—prostate cancer	0.000108	0.00072	CcSEcCtD
Linagliptin—Myalgia—Epirubicin—prostate cancer	0.000108	0.00072	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000108	0.000715	CcSEcCtD
Linagliptin—Urticaria—Prednisone—prostate cancer	0.000106	0.000701	CcSEcCtD
Linagliptin—Diarrhoea—Docetaxel—prostate cancer	0.000105	0.0007	CcSEcCtD
Linagliptin—Anaphylactic shock—Epirubicin—prostate cancer	0.000104	0.00069	CcSEcCtD
Linagliptin—Infection—Epirubicin—prostate cancer	0.000103	0.000686	CcSEcCtD
Linagliptin—Cough—Doxorubicin—prostate cancer	0.000103	0.000683	CcSEcCtD
Linagliptin—Diarrhoea—Capecitabine—prostate cancer	0.000102	0.000678	CcSEcCtD
Linagliptin—Skin disorder—Epirubicin—prostate cancer	0.000101	0.000671	CcSEcCtD
Linagliptin—Arthralgia—Doxorubicin—prostate cancer	0.0001	0.000666	CcSEcCtD
Linagliptin—Myalgia—Doxorubicin—prostate cancer	0.0001	0.000666	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	9.97e-05	0.000662	CcSEcCtD
Linagliptin—Hypersensitivity—Prednisone—prostate cancer	9.8e-05	0.00065	CcSEcCtD
Linagliptin—Rash—Docetaxel—prostate cancer	9.72e-05	0.000645	CcSEcCtD
Linagliptin—Dermatitis—Docetaxel—prostate cancer	9.71e-05	0.000645	CcSEcCtD
Linagliptin—Headache—Docetaxel—prostate cancer	9.66e-05	0.000641	CcSEcCtD
Linagliptin—Anaphylactic shock—Doxorubicin—prostate cancer	9.62e-05	0.000639	CcSEcCtD
Linagliptin—Infection—Doxorubicin—prostate cancer	9.56e-05	0.000635	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Epirubicin—prostate cancer	9.47e-05	0.000629	CcSEcCtD
Linagliptin—Rash—Capecitabine—prostate cancer	9.41e-05	0.000625	CcSEcCtD
Linagliptin—Dermatitis—Capecitabine—prostate cancer	9.4e-05	0.000624	CcSEcCtD
Linagliptin—Headache—Capecitabine—prostate cancer	9.35e-05	0.000621	CcSEcCtD
Linagliptin—Skin disorder—Doxorubicin—prostate cancer	9.35e-05	0.00062	CcSEcCtD
Linagliptin—Diarrhoea—Prednisone—prostate cancer	9.1e-05	0.000604	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Epirubicin—prostate cancer	8.98e-05	0.000596	CcSEcCtD
Linagliptin—Constipation—Epirubicin—prostate cancer	8.89e-05	0.00059	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Doxorubicin—prostate cancer	8.77e-05	0.000582	CcSEcCtD
Linagliptin—Rash—Prednisone—prostate cancer	8.38e-05	0.000557	CcSEcCtD
Linagliptin—Dermatitis—Prednisone—prostate cancer	8.37e-05	0.000556	CcSEcCtD
Linagliptin—Headache—Prednisone—prostate cancer	8.33e-05	0.000553	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Doxorubicin—prostate cancer	8.31e-05	0.000551	CcSEcCtD
Linagliptin—Urticaria—Epirubicin—prostate cancer	8.26e-05	0.000548	CcSEcCtD
Linagliptin—Constipation—Doxorubicin—prostate cancer	8.23e-05	0.000546	CcSEcCtD
Linagliptin—Hypersensitivity—Epirubicin—prostate cancer	7.66e-05	0.000509	CcSEcCtD
Linagliptin—Urticaria—Doxorubicin—prostate cancer	7.64e-05	0.000507	CcSEcCtD
Linagliptin—Diarrhoea—Epirubicin—prostate cancer	7.11e-05	0.000472	CcSEcCtD
Linagliptin—Hypersensitivity—Doxorubicin—prostate cancer	7.09e-05	0.000471	CcSEcCtD
Linagliptin—Diarrhoea—Doxorubicin—prostate cancer	6.58e-05	0.000437	CcSEcCtD
Linagliptin—Rash—Epirubicin—prostate cancer	6.56e-05	0.000435	CcSEcCtD
Linagliptin—Dermatitis—Epirubicin—prostate cancer	6.55e-05	0.000435	CcSEcCtD
Linagliptin—Headache—Epirubicin—prostate cancer	6.51e-05	0.000432	CcSEcCtD
Linagliptin—Rash—Doxorubicin—prostate cancer	6.07e-05	0.000403	CcSEcCtD
Linagliptin—Dermatitis—Doxorubicin—prostate cancer	6.06e-05	0.000402	CcSEcCtD
Linagliptin—Headache—Doxorubicin—prostate cancer	6.03e-05	0.0004	CcSEcCtD
Linagliptin—CYP3A4—Biological oxidations—GGT1—prostate cancer	2.81e-05	0.000463	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—NCOA1—prostate cancer	2.77e-05	0.000456	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—prostate cancer	2.74e-05	0.000452	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	2.73e-05	0.00045	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—prostate cancer	2.72e-05	0.000448	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	2.69e-05	0.000444	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GRHPR—prostate cancer	2.67e-05	0.00044	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—UGT2B17—prostate cancer	2.67e-05	0.00044	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CKMT2—prostate cancer	2.67e-05	0.00044	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—UGT2B15—prostate cancer	2.67e-05	0.00044	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—prostate cancer	2.65e-05	0.000438	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—RXRA—prostate cancer	2.63e-05	0.000434	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—prostate cancer	2.57e-05	0.000424	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC22A1—prostate cancer	2.54e-05	0.00042	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—prostate cancer	2.54e-05	0.000419	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—COMT—prostate cancer	2.53e-05	0.000418	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTP1—prostate cancer	2.52e-05	0.000416	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTM3—prostate cancer	2.51e-05	0.000414	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NAGLU—prostate cancer	2.51e-05	0.000414	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AOX1—prostate cancer	2.51e-05	0.000414	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MBTPS1—prostate cancer	2.51e-05	0.000414	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—RFK—prostate cancer	2.51e-05	0.000414	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SULT2B1—prostate cancer	2.51e-05	0.000414	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PGAM2—prostate cancer	2.51e-05	0.000414	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	2.5e-05	0.000412	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	2.49e-05	0.00041	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—GNG5—prostate cancer	2.42e-05	0.000399	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—prostate cancer	2.38e-05	0.000393	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AMACR—prostate cancer	2.38e-05	0.000392	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP3A43—prostate cancer	2.38e-05	0.000392	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SRD5A2—prostate cancer	2.38e-05	0.000392	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NAT1—prostate cancer	2.38e-05	0.000392	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—DEGS1—prostate cancer	2.38e-05	0.000392	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—prostate cancer	2.35e-05	0.000388	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTM1—prostate cancer	2.32e-05	0.000382	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—AKT1—prostate cancer	2.29e-05	0.000378	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	2.29e-05	0.000377	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—prostate cancer	2.27e-05	0.000375	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HSD17B1—prostate cancer	2.27e-05	0.000374	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	2.2e-05	0.000363	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HAO1—prostate cancer	2.17e-05	0.000358	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	2.17e-05	0.000358	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—prostate cancer	2.16e-05	0.000357	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—PRKACB—prostate cancer	2.06e-05	0.00034	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—prostate cancer	2.05e-05	0.000339	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—prostate cancer	2.02e-05	0.000334	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HPGD—prostate cancer	2.02e-05	0.000334	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—B4GALT4—prostate cancer	2.02e-05	0.000334	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—prostate cancer	1.99e-05	0.000329	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—prostate cancer	1.95e-05	0.000322	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—NCOA2—prostate cancer	1.94e-05	0.000321	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—TNFRSF21—prostate cancer	1.9e-05	0.000314	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	1.86e-05	0.000306	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP7B1—prostate cancer	1.85e-05	0.000305	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MTAP—prostate cancer	1.85e-05	0.000305	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—prostate cancer	1.85e-05	0.000305	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—prostate cancer	1.81e-05	0.000299	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SULT1E1—prostate cancer	1.8e-05	0.000297	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SRD5A1—prostate cancer	1.8e-05	0.000297	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ADI1—prostate cancer	1.77e-05	0.000292	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—TST—prostate cancer	1.77e-05	0.000292	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PSAT1—prostate cancer	1.77e-05	0.000292	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CSAD—prostate cancer	1.77e-05	0.000292	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GRHL1—prostate cancer	1.77e-05	0.000292	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CBR1—prostate cancer	1.77e-05	0.000292	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—prostate cancer	1.76e-05	0.000291	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—prostate cancer	1.74e-05	0.000288	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ACSL4—prostate cancer	1.72e-05	0.000284	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HSD17B3—prostate cancer	1.72e-05	0.000284	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—prostate cancer	1.7e-05	0.000281	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—prostate cancer	1.7e-05	0.000281	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—UMPS—prostate cancer	1.65e-05	0.000272	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PHGDH—prostate cancer	1.65e-05	0.000272	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ARG2—prostate cancer	1.65e-05	0.000272	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CKMT2—prostate cancer	1.64e-05	0.000271	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.64e-05	0.000271	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GRHPR—prostate cancer	1.64e-05	0.000271	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.64e-05	0.000271	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—NCOA1—prostate cancer	1.64e-05	0.00027	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—prostate cancer	1.62e-05	0.000268	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—LDHB—prostate cancer	1.62e-05	0.000267	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP3A5—prostate cancer	1.59e-05	0.000262	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—prostate cancer	1.58e-05	0.00026	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—RXRA—prostate cancer	1.56e-05	0.000257	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—RFK—prostate cancer	1.54e-05	0.000255	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTM3—prostate cancer	1.54e-05	0.000255	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AOX1—prostate cancer	1.54e-05	0.000255	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NAGLU—prostate cancer	1.54e-05	0.000255	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PGAM2—prostate cancer	1.54e-05	0.000255	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.54e-05	0.000255	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.54e-05	0.000255	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—prostate cancer	1.54e-05	0.000254	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—TCN2—prostate cancer	1.53e-05	0.000253	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—UCP3—prostate cancer	1.53e-05	0.000253	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PDHA1—prostate cancer	1.53e-05	0.000253	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTA3—prostate cancer	1.53e-05	0.000253	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AMACR—prostate cancer	1.46e-05	0.000242	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.46e-05	0.000242	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.46e-05	0.000242	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NAT1—prostate cancer	1.46e-05	0.000242	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—DEGS1—prostate cancer	1.46e-05	0.000242	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HSD3B1—prostate cancer	1.46e-05	0.000241	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC22A3—prostate cancer	1.46e-05	0.000241	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—prostate cancer	1.41e-05	0.000233	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—prostate cancer	1.41e-05	0.000233	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—TBXAS1—prostate cancer	1.4e-05	0.000231	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTA4—prostate cancer	1.4e-05	0.000231	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.4e-05	0.000231	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	1.38e-05	0.000228	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTA2—prostate cancer	1.37e-05	0.000225	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ABCG5—prostate cancer	1.35e-05	0.000223	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SULT1A1—prostate cancer	1.35e-05	0.000223	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTA1—prostate cancer	1.32e-05	0.000217	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	1.31e-05	0.000216	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HSD3B2—prostate cancer	1.3e-05	0.000215	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTO1—prostate cancer	1.3e-05	0.000215	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NAT2—prostate cancer	1.3e-05	0.000215	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PLCB2—prostate cancer	1.25e-05	0.000206	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—LRP2—prostate cancer	1.25e-05	0.000206	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP2C18—prostate cancer	1.25e-05	0.000206	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HPGD—prostate cancer	1.25e-05	0.000206	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.25e-05	0.000206	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—P4HB—prostate cancer	1.22e-05	0.000202	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	1.2e-05	0.000198	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC22A1—prostate cancer	1.19e-05	0.000197	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—PPARA—prostate cancer	1.19e-05	0.000197	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.17e-05	0.000193	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SULT2A1—prostate cancer	1.16e-05	0.000192	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	1.16e-05	0.000192	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MED12—prostate cancer	1.14e-05	0.000188	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MTAP—prostate cancer	1.14e-05	0.000188	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.14e-05	0.000188	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GNG5—prostate cancer	1.13e-05	0.000187	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.11e-05	0.000183	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.11e-05	0.000183	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NCOA3—prostate cancer	1.09e-05	0.00018	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ACSL4—prostate cancer	1.06e-05	0.000175	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.06e-05	0.000175	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HPGDS—prostate cancer	1.04e-05	0.000172	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP2C19—prostate cancer	1.03e-05	0.000171	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—UMPS—prostate cancer	1.02e-05	0.000168	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PHGDH—prostate cancer	1.02e-05	0.000168	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ARG2—prostate cancer	1.02e-05	0.000168	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTT1—prostate cancer	1.01e-05	0.000167	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ACHE—prostate cancer	1.01e-05	0.000167	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP2A6—prostate cancer	9.98e-06	0.000165	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—LDHB—prostate cancer	9.95e-06	0.000164	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	9.8e-06	0.000162	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP3A5—prostate cancer	9.77e-06	0.000161	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AKR1C3—prostate cancer	9.71e-06	0.00016	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PRKACB—prostate cancer	9.66e-06	0.000159	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP17A1—prostate cancer	9.56e-06	0.000158	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	9.45e-06	0.000156	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PDHA1—prostate cancer	9.44e-06	0.000156	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTA3—prostate cancer	9.44e-06	0.000156	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—UCP3—prostate cancer	9.44e-06	0.000156	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—TCN2—prostate cancer	9.44e-06	0.000156	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NCOA2—prostate cancer	9.11e-06	0.00015	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC22A3—prostate cancer	9e-06	0.000149	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HSD3B1—prostate cancer	9e-06	0.000149	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC5A5—prostate cancer	8.69e-06	0.000143	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTA4—prostate cancer	8.63e-06	0.000142	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—TBXAS1—prostate cancer	8.63e-06	0.000142	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP2E1—prostate cancer	8.49e-06	0.00014	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTA2—prostate cancer	8.41e-06	0.000139	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NQO1—prostate cancer	8.39e-06	0.000139	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SULT1A1—prostate cancer	8.31e-06	0.000137	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ABCG5—prostate cancer	8.31e-06	0.000137	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—TH—prostate cancer	8.27e-06	0.000137	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP3A4—prostate cancer	8.18e-06	0.000135	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTA1—prostate cancer	8.11e-06	0.000134	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP1B1—prostate cancer	8.05e-06	0.000133	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HSD3B2—prostate cancer	8.02e-06	0.000132	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTO1—prostate cancer	8.02e-06	0.000132	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NAT2—prostate cancer	8.02e-06	0.000132	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GGT1—prostate cancer	7.79e-06	0.000129	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PLCB2—prostate cancer	7.69e-06	0.000127	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP2C18—prostate cancer	7.69e-06	0.000127	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—LRP2—prostate cancer	7.69e-06	0.000127	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NCOA1—prostate cancer	7.68e-06	0.000127	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP19A1—prostate cancer	7.56e-06	0.000125	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—P4HB—prostate cancer	7.54e-06	0.000125	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC22A1—prostate cancer	7.34e-06	0.000121	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—RXRA—prostate cancer	7.3e-06	0.00012	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SULT2A1—prostate cancer	7.15e-06	0.000118	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MED12—prostate cancer	7.04e-06	0.000116	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—COMT—prostate cancer	7.03e-06	0.000116	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTP1—prostate cancer	7e-06	0.000116	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GNG5—prostate cancer	6.98e-06	0.000115	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ITPR1—prostate cancer	6.89e-06	0.000114	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NCOA3—prostate cancer	6.72e-06	0.000111	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—TYMS—prostate cancer	6.51e-06	0.000107	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTM1—prostate cancer	6.43e-06	0.000106	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HPGDS—prostate cancer	6.41e-06	0.000106	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP2C19—prostate cancer	6.37e-06	0.000105	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—LPL—prostate cancer	6.31e-06	0.000104	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ACHE—prostate cancer	6.22e-06	0.000103	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTT1—prostate cancer	6.22e-06	0.000103	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP2A6—prostate cancer	6.15e-06	0.000101	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP1A1—prostate cancer	6.1e-06	0.000101	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ERCC2—prostate cancer	6.05e-06	9.98e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AKR1C3—prostate cancer	5.98e-06	9.87e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PRKACB—prostate cancer	5.95e-06	9.82e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP17A1—prostate cancer	5.89e-06	9.72e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MTHFR—prostate cancer	5.68e-06	9.38e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NCOA2—prostate cancer	5.61e-06	9.26e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PPARA—prostate cancer	5.58e-06	9.2e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.35e-06	8.84e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CAV1—prostate cancer	5.24e-06	8.65e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.23e-06	8.63e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NQO1—prostate cancer	5.17e-06	8.53e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—TH—prostate cancer	5.1e-06	8.41e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP1B1—prostate cancer	4.96e-06	8.18e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GGT1—prostate cancer	4.8e-06	7.92e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CG—prostate cancer	4.78e-06	7.88e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NCOA1—prostate cancer	4.73e-06	7.8e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.66e-06	7.69e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—INS—prostate cancer	4.52e-06	7.46e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—RXRA—prostate cancer	4.5e-06	7.42e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CREBBP—prostate cancer	4.43e-06	7.31e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—COMT—prostate cancer	4.33e-06	7.15e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTP1—prostate cancer	4.31e-06	7.12e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ITPR1—prostate cancer	4.24e-06	7e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CD—prostate cancer	4.2e-06	6.93e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—TYMS—prostate cancer	4.01e-06	6.62e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NOS3—prostate cancer	3.96e-06	6.54e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTM1—prostate cancer	3.96e-06	6.54e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—LPL—prostate cancer	3.89e-06	6.42e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.76e-06	6.2e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ERCC2—prostate cancer	3.73e-06	6.15e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CB—prostate cancer	3.66e-06	6.04e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTGS2—prostate cancer	3.63e-06	5.98e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MTHFR—prostate cancer	3.5e-06	5.78e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PPARA—prostate cancer	3.44e-06	5.67e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CAV1—prostate cancer	3.23e-06	5.33e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTEN—prostate cancer	3.16e-06	5.22e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—EP300—prostate cancer	3.02e-06	4.98e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.94e-06	4.86e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—INS—prostate cancer	2.79e-06	4.6e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CREBBP—prostate cancer	2.73e-06	4.5e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.59e-06	4.27e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NOS3—prostate cancer	2.44e-06	4.03e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.25e-06	3.72e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTGS2—prostate cancer	2.23e-06	3.69e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CA—prostate cancer	2.23e-06	3.68e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTEN—prostate cancer	1.95e-06	3.22e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—EP300—prostate cancer	1.86e-06	3.07e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AKT1—prostate cancer	1.82e-06	3.01e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.37e-06	2.27e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AKT1—prostate cancer	1.12e-06	1.85e-05	CbGpPWpGaD
